Overview: The biotechnology industry's daily monitor, with emphasis on clinical trials, dealmaking, regulatory issues, and FDA decisions.

Newsletter Subscribers: 70,000+

Publishing Schedule: daily

Audience: Senior executives and business decision makers at biotech, pharmaceutical, and related drug development companies.

Past Advertisers Include: Novozymes, Agilent Technologies, Applied Biosystems, Ajinomoto, GenPathway

Reader Demographics

79% of FierceBiotech readers have referred the publication to a friend or colleague.

Job Function
Executive Management/BusDev/Sales - 48%
Research & Development - 20%
Finance, Investment - 7%
Student - 2%
Other - 23%

Region
North America - 87%
United States - 80%
Canada - 7%
Outside North America - 13%
Europe - 8%
Asia - 4%
Other - 1%

Type of Company
Emerging & Mid-Tier Biotech/Pharma - 24%
Large Pharma - 8%
Clinical/Contract Research Organization (CRO) - 6%
Service/Supply/Manufacturing - 11%
Diagnostic & Device - 4%
Academic - 7%
Gov't, Non-Profit - 5%
Other - 35%

Percent of FierceBiotech readers who recommend or approve purchasing
Lab Supplies & Equipment - 41%
Outsourcing Partners - CROs - 36%
Outsourcing Partners - other - 43%
IT/Software - 31%
Legal/Patent Services - 32%
Financial/Accounting Services - 26%

Top Companies Represented

Abbot Laboratories
Amgen
Aventis
Barr Laboratories
Bayer
BIO
Biogen IDC
Boehringer Ingelheim
Bristol Myers Squibb
Cambrex
Celera Genomics
Celgene
Centocor
Charles River Laboratories
Chiron
Eli Lilly
Elsevier
EMD Biosciences
Exelixis
Fischer Scientific
Genentech
Genzyme
GlaxoSmithKline
Ingenix
Invitrogen
Johnson & Johnson
MedImmune
Medtronic
Merck
Neurocrine Biosciences
Novartis
Pfizer
Quintiles
Regeneron Pharmaceuticals
Sanofi-Aventis
Schering-Plough
Theravance, Inc.
Therion Biologics
Wyeth BioPharma
Xencor, Inc.
ZymoGenetics